111 related articles for article (PubMed ID: 24265404)
1. Update on nonserous ovarian cancer trials.
Fujiwara K; Yoshida H; Hasegawa K
Ann Oncol; 2013 Dec; 24 Suppl 10():x46-x47. PubMed ID: 24265404
[No Abstract] [Full Text] [Related]
2. Mucinous ovarian cancer: current therapeutic targets, preclinical progress, and experimental drugs.
Moioli M; Barra F; Maramai M; Valenzano Menada M; Vellone VG; Costantini S; Ferrero S
Expert Opin Investig Drugs; 2019 Dec; 28(12):1025-1029. PubMed ID: 31726889
[No Abstract] [Full Text] [Related]
3. Mucinous ovarian cancer: A therapeutic review.
Xu W; Rush J; Rickett K; Coward JI
Crit Rev Oncol Hematol; 2016 Jun; 102():26-36. PubMed ID: 27083591
[TBL] [Abstract][Full Text] [Related]
4. Recent Insights into Mucinous Ovarian Carcinoma.
Ricci F; Affatato R; Carrassa L; Damia G
Int J Mol Sci; 2018 May; 19(6):. PubMed ID: 29795040
[TBL] [Abstract][Full Text] [Related]
5. Mucinous epithelial ovarian carcinoma.
Perren TJ
Ann Oncol; 2016 Apr; 27 Suppl 1():i53-i57. PubMed ID: 27141073
[TBL] [Abstract][Full Text] [Related]
6. [Low-grade serous, mucinous carcinoma].
Nakayama K; Kyo S
Gan To Kagaku Ryoho; 2015 Feb; 42(2):179-82. PubMed ID: 25834916
[No Abstract] [Full Text] [Related]
7. A case of progressive mucinous ovarian cancer of low malignant potential responsive to biologic therapy with Bevacizumab.
Winer I; Buckanovich RJ
Gynecol Oncol; 2010 Mar; 116(3):578-9. PubMed ID: 19897232
[No Abstract] [Full Text] [Related]
8. Dual inhibition of phosphatidylinositol 3'-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach for mucinous adenocarcinoma of the ovary.
Kudoh A; Oishi T; Itamochi H; Sato S; Naniwa J; Sato S; Shimada M; Kigawa J; Harada T
Int J Gynecol Cancer; 2014 Mar; 24(3):444-53. PubMed ID: 24552895
[TBL] [Abstract][Full Text] [Related]
9. Ovarian cancer treatments on the horizon.
Schmidt C
J Natl Cancer Inst; 2011 Sep; 103(17):1284-5. PubMed ID: 21852261
[No Abstract] [Full Text] [Related]
10. Does the primary site really matter? Profiling mucinous ovarian cancers of uncertain primary origin (MO-CUP) to personalise treatment and inform the design of clinical trials.
Meagher NS; Schuster K; Voss A; Budden T; Pang CNI; deFazio A; Ramus SJ; Friedlander ML
Gynecol Oncol; 2018 Sep; 150(3):527-533. PubMed ID: 30054102
[TBL] [Abstract][Full Text] [Related]
11. [Molecular targeted therapies for epithelial ovarian cancer].
Itamochi H; Kigawa J
Nihon Rinsho; 2012 Jun; 70 Suppl 4():622-7. PubMed ID: 23156321
[No Abstract] [Full Text] [Related]
12. Optimal first-line treatment in ovarian cancer.
Raja FA; Chopra N; Ledermann JA
Ann Oncol; 2012 Sep; 23 Suppl 10():x118-27. PubMed ID: 22987945
[TBL] [Abstract][Full Text] [Related]
13. [A case report of acute renal failure induced by melphalan in a patient with ovarian cancer].
Kashimura M; Kondo M; Abe T; Shinohara M; Baba S
Gan No Rinsho; 1988 Nov; 34(14):2015-8. PubMed ID: 2849690
[TBL] [Abstract][Full Text] [Related]
14. [Molecular targeting therapy for gynecologic cancer].
Nakayama K; Miyazaki K
Nihon Rinsho; 2012 Nov; 70 Suppl 8():524-8. PubMed ID: 23513895
[No Abstract] [Full Text] [Related]
15. A phase II clinical trial of topotecan in Japanese patients with relapsed ovarian carcinoma.
Aoki D; Katsumata N; Nakanishi T; Kigawa J; Fujiwara K; Takehara K; Kamiura S; Hiura M; Hatae M; Sugiyama T; Ochiai K; Noda K
Jpn J Clin Oncol; 2011 Mar; 41(3):320-7. PubMed ID: 20974678
[TBL] [Abstract][Full Text] [Related]
16. The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer.
Mabuchi S; Kuroda H; Takahashi R; Sasano T
Gynecol Oncol; 2015 Apr; 137(1):173-9. PubMed ID: 25677064
[TBL] [Abstract][Full Text] [Related]
17. Activity of chemotherapy in mucinous epithelial ovarian cancer: a retrospective study.
Pisano C; Greggi S; Tambaro R; Losito S; Iodice F; Di Maio M; Ferrari E; Falanga M; Formato R; Iaffaioli VR; Pignata S
Anticancer Res; 2005; 25(5):3501-5. PubMed ID: 16101169
[TBL] [Abstract][Full Text] [Related]
18. Epithelial ovarian cancer: focus on targeted therapy.
Pliarchopoulou K; Pectasides D
Crit Rev Oncol Hematol; 2011 Jul; 79(1):17-23. PubMed ID: 20674385
[TBL] [Abstract][Full Text] [Related]
19. [Treatment of clear cell adenocarcinoma and mucinous adenocarcinoma].
Saga Y; Takei Y; Fujiwara H; Suzuki M
Nihon Rinsho; 2012 Jun; 70 Suppl 4():634-7. PubMed ID: 23156323
[No Abstract] [Full Text] [Related]
20. American Society of Clinical Oncology 2011 Annual Meeting update: summary of selected gynecologic cancer abstracts.
Tewari KS; Monk BJ
Gynecol Oncol; 2011 Aug; 122(2):209-12. PubMed ID: 21763890
[No Abstract] [Full Text] [Related]
[Next] [New Search]
